Skip to content

Dexmedetomidine Added to Ropivacaine for Transversus Abdominis Plane Block Reduces the Incidence of Perioperative Neurocognitive Disorders: a Single Centre Randomized Controlled Trial

Dexmedetomidine Added to Ropivacaine for Transversus Abdominis Plane Block Reduces the Incidence of Perioperative Neurocognitive Disorders: a Single Centre Randomized Controlled Trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100046876
Enrollment
Unknown
Registered
2021-05-29
Start date
2021-05-30
Completion date
Unknown
Last updated
2022-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perioperative Neurocognitive Disorders

Interventions

experimental group:0.5% ropivacaine + 1µg/kg dexmedetomidine, 20ml

Sponsors

Yibin Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. All participants have signed an informed consent form; 2. Aged >= 60 years; 3. American society of anesthesiologists (American society of anesthesiologists, ASA) classification I-III; 4. Operation time >= 120min; 5. The preoperative activities of daily living (ADLs) score >= 95 points.

Exclusion criteria

Exclusion criteria: 1. Patients with mental and psychological disorders; 2. Long-term history of alcohol and drug abuse, long-term use of Valium or opioids; 3. Preoperative mini-mental state examination (MMSE) scores to determine patients with postoperative cognitive dysfunction (such as patients with Alzheimer's disease); 4. Those who have adverse reactions to the anesthetics used; 5. Patients with infection and abnormal blood coagulation at the puncture site; 6. Patients with diabetes and severe organ dysfunction.

Design outcomes

Primary

MeasureTime frame
Perioperative incidence of neurocognitive impairment;

Countries

China

Contacts

Public ContactYu Deshui

Yibin Second People's Hospital

568457863@qq.com+86 15680391118

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026